
Abivax SA (ABVX) Stock Forecast & Price Target
Abivax SA (ABVX) Analyst Ratings
Bulls say
Abivax is currently evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. The company is also conducting preclinical studies to evaluate the potential of combination therapy and the use of obefazimod in other inflammatory and immunological diseases. With a best-in-class profile, a strong pipeline, and the potential for a blockbuster drug in the inflammatory bowel disease market, Abivax is well-positioned for success in the biotech industry.
Bears say
Abivax is a clinical-stage biotechnology company focused on developing therapeutics for inflammatory bowel diseases. A bolstered balance sheet and confidence in obe's ability to treat refractory patients may provide some opportunities, however, there are concerns regarding the observed malignancy signals and the lack of correlation between NMSCs and skin lesions, which may limit the commercial potential and overall safety profile of obefazimod. Additionally, discussions with former FDA leaders suggest that obefazimod is unlikely to receive prominent warning language.
This aggregate rating is based on analysts' research of Abivax SA and is not a guaranteed prediction by Public.com or investment advice.
Abivax SA (ABVX) Analyst Forecast & Price Prediction
Start investing in Abivax SA (ABVX)
Order type
Buy in
Order amount
Est. shares
0 shares